Metraipolis › archive › dc_1507c49047fa
Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42167248
- DOI
- 10.1016/j.xcrm.2026.102827
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T09:55:40.250Z
- SHA-256 of the archived text
de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709- Stable URL of this page
https://metraipolis.com/documento/dc_1507c49047fa
How to cite
Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248 — Europe PMC (en), https://europepmc.org/article/MED/42167248 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1507c49047fa (Metraipolis archive dc_1507c49047fa, sha256 de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709)
BibTeX
@misc{dc1507c49047fa,
title = {Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42167248},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1507c49047fa; sha256 de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42167248. Agents can read the archived copy with the MCP tool read_document.